Cardiovascular biomarkers: increasing impact of laboratory medicine in cardiology practice (Q37207281)

18 August 2017

1 reference

title

Cardiovascular biomarkers: increasing impact of laboratory medicine in cardiology practice (English)

1 reference

18 August 2017

0 references

1 reference

2

Aldo Clerico

1 reference

18 August 2017

1

Simona Vittorini

1 reference

18 August 2017

publication date

1 January 2008

1 reference

Clinical Chemistry and Laboratory Medicine

18 August 2017

published in

1 reference

18 August 2017

volume

46

1 reference

18 August 2017

issue

6

1 reference

18 August 2017

page(s)

748-763

1 reference

The increasing impact of laboratory medicine on clinical cardiology

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

Biomarkers of cardiovascular disease: molecular basis and practical considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

Biomarkers in acute cardiac disease: the present and the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

Cardiac markers and risk stratification: an integrated approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

The exciting story of cardiac biomarkers: from retrospective detection to gold diagnostic standard for acute myocardial infarction and more.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

Myocardial infarction redefined--a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

Diagnostic accuracy and prognostic relevance of the measurement of cardiac natriuretic peptides: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

A systematic review of the diagnostic accuracy of natriuretic peptides for heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

Novel and potential future biomarkers for assessment of the severity and prognosis of chronic heart failure : a clinical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

Prognostic relevance of atrial fibrillation in patients with chronic heart failure on long-term treatment with beta-blockers: results from COMET.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

"New" risk factors for atherosclerotic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

Role of infections in atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

Chlamydia pneumoniae and atherosclerotic risk in populations: the role of seroepidemiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

The association of infection and coronary artery disease: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

Lipoprotein (a) and stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

The role of lipoprotein[a] in atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

Novel risk factors for atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

Assessment of subclinical atherosclerosis and cardiovascular risk.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

Genes encoding fibrinogen and cardiovascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

Prognostic value of serum gamma-glutamyl transferase activity after myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

Systemic inflammation as a cardiovascular disease risk factor and as a potential target for drug therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

Angiotensin II as a cardiovascular risk factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

High sensitivity C-reactive protein: an emerging role in cardiovascular risk assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

Microalbuminuria, an integrated marker of cardiovascular risk in essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

Homocyst(e)ine and cardiovascular disease: a systematic review of the evidence with special emphasis on case-control studies and nested case-control studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

Homocysteine and cardiovascular disease: current evidence and future prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

Obesity, physical inactivity, and risk for cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

Uric acid and cardiovascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

Stress: a risk factor for serious illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

Evidence for infectious agents in cardiovascular disease and atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

Review of evidence for a connection between Chlamydia pneumoniae and atherosclerotic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

Hypertriglyceridemia and risk of coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

AHA/ACC scientific statement: Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

Task force #1--magnitude of the prevention problem: opportunities and challenges. 33rd Bethesda Conference

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

Genetic markers: progress and potential for cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

Gene expression analysis of cardiovascular diseases: novel insights into biology and clinical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

Genetics of cardiovascular disease with emphasis on atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

Genetics of idiopathic dilated cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

Molecular genetics of left ventricular dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

Implications of pharmacogenomics for drug development and clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

Biomarkers and surrogate endpoints: preferred definitions and conceptual framework

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

Surrogate endpoints in clinical trials: definition and operational criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

Evaluation of surrogate endpoints in randomized experiments with mixed discrete and continuous outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

Inherent biological variation and reference values

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Standards for Reporting of Diagnostic Accuracy

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

Systematic reviews in health care: Systematic reviews of evaluations of diagnostic and screening tests

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

The architecture of diagnostic research

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

Statistical evaluation of prognostic versus diagnostic models: beyond the ROC curve

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Münster (PROCAM) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

In search of fewer independent risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

Observed differences in diagnostic test accuracy between patient subgroups: is it real or due to reference standard misclassification?

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

Comparison of the diagnostic accuracy of brain natriuretic peptide (BNP) and the N-terminal part of the propeptide of BNP immunoassays in chronic and acute heart failure: a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

Comparison of brain natriuretic peptide (BNP) and amino-terminal ProBNP for early diagnosis of heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction—Executive Summary

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

Impact of the recommendations for the redefinition of myocardial infarction on diagnosis and prognosis in an unselected United Kingdom cohort with suspected cardiac chest pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

The new definition of myocardial infarction and the impact of troponin determination on clinical practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

Troponin T levels and risk of 30-day outcomes in patients with the acute coronary syndrome: prospective verification in the GUSTO-IV trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

Plasma 99th percentile reference limits for cardiac troponin and creatine kinase MB mass for use with European Society of Cardiology/American College of Cardiology consensus recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

Evaluation of imprecision for cardiac troponin assays at low-range concentrations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

Risk stratification using a combination of cardiac troponin T and brain natriuretic peptide in patients hospitalized for worsening chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

Sepsis-associated myocardial dysfunction: diagnostic and prognostic impact of cardiac troponins and natriuretic peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

Plasma brain natriuretic peptide and cardiac troponin I concentrations after adult cardiac surgery: association with postoperative cardiac dysfunction and 1-year mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

Relationship between anemia, cardiac troponin I, and B-type natriuretic peptide levels and mortality in patients with advanced heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

Measurements of baseline and follow-up concentrations of cardiac troponin-T and brain natriuretic peptide in patients with heart failure from various etiologies

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

Cardiac endocrine function is an essential component of the homeostatic regulation network: physiological and clinical implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

Plasma brain natriuretic peptide measured by fully-automated immunoassay and by immunoradiometric assay compared

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

Analytical performance and diagnostic accuracy of a fully-automated electrochemiluminescent assay for the N-terminal fragment of the pro-peptide of brain natriuretic peptide in patients with cardiomyopathy: comparison with immunoradiometric assay me

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

Analytical performance and clinical results of a fully automated MEIA system for brain natriuretic peptide assay: comparison with a point of care testing method.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

Analytical performance and diagnostic accuracy of immunometric assays for the measurement of plasma B-type natriuretic peptide (BNP) and N-terminal proBNP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

Comparison of a fully automated immunoassay with a point-of-care testing method for B-type natriuretic peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

Natriuretic peptides for risk stratification of patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

Executive summary: HFSA 2006 Comprehensive Heart Failure Practice Guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

National Academy of Clinical Biochemistry Laboratory Medicine practice guidelines: Clinical utilization of cardiac biomarker testing in heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

National Academy of Clinical Biochemistry laboratory medicine practice guidelines: use of cardiac troponin and B-type natriuretic peptide or N-terminal proB-type natriuretic peptide for etiologies other than acute coronary syndromes and heart failur

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: report from the population science discussion group

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

Covered stent septal ablation for hypertrophic obstruction cardiomyopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

Measurement of matrix metalloproteinases and tissue inhibitors of metalloproteinases in blood and tissues. Clinical and experimental applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

Matrix metalloproteinases as valid clinical targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

Deoxyribonucleic acid damage in human lymphocytes after percutaneous transluminal coronary angioplasty

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

Oxidation of low-density lipoprotein in atherosclerosis from basic biochemistry to clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

Free radicals, mitochondria, and oxidized lipids: the emerging role in signal transduction in vascular cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

Role of endothelial shear stress in the natural history of coronary atherosclerosis and vascular remodeling: molecular, cellular, and vascular behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

Stressing the obvious? Cell stress and cell stress proteins in cardiovascular disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

Gamma-glutamyltransferase, atherosclerosis, and cardiovascular disease: triggering oxidative stress within the plaque

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

Gamma-glutamyltransferase as a risk factor for cardiovascular disease mortality: an epidemiological investigation in a cohort of 163,944 Austrian adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

Gamma Glutamyl Transferase and Metabolic Syndrome, Cardiovascular Disease, and Mortality Risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

Atherosclerosis and acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

Low-dose aspirin for the prevention of atherothrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

Aspirin resistance: position paper of the Working Group on Aspirin Resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

Resistance to antiplatelet drugs: molecular mechanisms and laboratory detection

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

Translating genomic biomarkers into clinically useful diagnostics

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

Systems biology, proteomics, and the future of health care: toward predictive, preventative, and personalized medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

Genetic susceptibility to coronary artery disease: from promise to progress.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

Molecular and cellular basis of congenital heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

Legal, ethical, and social issues in human genome research

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

The nature and significance of behavioural genetic information

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

Genetic instability and atherosclerosis: can somatic mutations account for the development of cardiovascular diseases?

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

Discovery of biomarker candidates within disease by protein profiling: principles and concepts

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

The human disease network

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

Molecular genetics of coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

Genetic susceptibility to myocardial infarction and coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

The PAI-1 4G/5G gene polymorphism and ischemic stroke: an association study and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

C-reactive protein gene polymorphisms, C-reactive protein blood levels, and cardiovascular disease risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

Platelet genomics and the risk of atherothrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

Three endothelial nitric oxide (NOS3) gene polymorphisms in hypertensive and normotensive individuals: meta-analysis of 53 studies reveals evidence of publication bias

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

Practical Implementation of the Guidelines for Unstable Angina/Non–ST-Segment Elevation Myocardial Infarction in the Emergency Department

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.188

21 January 2018

Identifiers

DOI

10.1515/CCLM.2008.188

1 reference

18 August 2017

1 reference